GI DYNAMICS, INC. (OTCMKTS:GIDYL) Files An 8-K Regulation FD Disclosure

GI DYNAMICS, INC. (OTCMKTS:GIDYL) Files An 8-K Regulation FD Disclosure
Item 7.01

The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

By filing this Current Report on Form 8-K and furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the announcement and newsletter attached hereto as Exhibits 99.1 and 99.2, respectively. The information contained in the announcement and newsletter are summaries that are intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The Company cautions you that the announcement and newsletter attached hereto as Exhibits 99.1 and 99.2, respectively, contain forward-looking statements. These forward-looking statements are based on our management’s current estimates and expectations of future events as of the date of the date of the announcement and newsletter, respectively. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern, our ability to maintain compliance with our obligations under the loan documents with Crystal Amber Fund Limited, obtaining and maintaining regulatory approvals required to market and sell our products; obtaining funding from third parties; the consequences of stopping the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the SEC. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.

(d) Exhibits

99.1 Announcement, dated October 3, 2019 (EST).
99.2 Newsletter, dated October 3, 2019 (EST).

EX-99.1 2 f8k100319ex99-1_gidynamics.htm ANNOUNCEMENT,…
To view the full exhibit click here

An ad to help with our costs